Recognition, pathophysiology, and management of acute myocardial infarction

American Journal of Health-System Pharmacy

Volumn 58, Issue 18, 2001, Pages 1709-1718

  Cheng, J W M ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

Angiotensin converting enzyme inhibitors; Diagnosis; Myocardial infarction; Nitrates; Platelet aggregation inhibitors; Sympatholytic agents; Thrombolytic agents

Indexed keywords

ADRENERGIC RECEPTOR BLOCKING AGENT; ANTITHROMBOCYTIC AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; FIBRINOLYTIC AGENT; NITRATE;

ACUTE HEART INFARCTION; ANGINA PECTORIS; ATHEROSCLEROSIS; ATHEROSCLEROTIC PLAQUE; BLOOD VESSEL INJURY; CIRCADIAN RHYTHM; CLINICAL FEATURE; ELECTROCARDIOGRAM; HUMAN; LONG TERM CARE; MACROPHAGE; PATHOPHYSIOLOGY; PRIORITY JOURNAL; Q WAVE; REVIEW; SURVIVAL; THROMBOSIS;

EID: 0035884227     PISSN: 10792082     EISSN: None     Source Type: Journal    
DOI: 10.1093/ajhp/58.18.1709     Document Type: Review

References (127)

1. Acute coronary syndromes: Unstable angina and non-Q-wave myocardial infarction
2. Primary prevention of coronary heart disease: Guidance from Framingham
3. A definition of advanced types of atherosclerotic lesions and a histologic classification of atherosclerosis: A report from the committee on arteriosclerosis
4. Pathophysiology and clinical significance of atherosclerotic plaque rupture
5. From plaque biology to clinical setting
6. Mechanisms leading to myocardial infarction: Insights from studies of vascular biology
7. Pathophysiology of plaque rupture
8. Coronary risk factors and plaque morphology in men with coronary artery disease who died suddenly
9. Pathophysiology of acute coronary syndromes leading to acute myocardial infarction
10. Influence of plaque configuration and stress distribution on fissuring of coronary atherosclerotic plaques
11. Circadian variation of total ischaemic burden and its alteration with anti-anginal agent
12. Circadian rhythms and coronary artery disease
13. Human monocyte-derived macrophages induce collagen breakdown in fibrous caps of atherosclerotic plaques: Potential role of matrix-degrading metalloproteinases and implications for plaque rupture
14. Macrophage foam cells from experimental atheroma constitutively produce matrix-degrading proteinases
15. Molecular basis of the acute coronary syndromes
16. Reactive oxygen species produced by macrophage-derived foam cells regulate the activity of vascular matrix metalloproteinases in vivo: Implications for atherosclerotic plaque stability
17. Tissue factor is induced by monocyte chemoattractant protein-1 in human aortic smooth muscle and THP-1 cells
18. Apoptosis is abundant in human atherosclerotic lesions, especially in inflammatory cells (macrophages and T cells), and may contribute to the accumulation of gruel and plaque instability
19. Infection and coronary heart disease
20. Chronic infections and coronary heart disease: Is there a link?
21. Atherosclerosis induced by infection with herpesvirus
22. Chlamydia pneumoniae, strain TWAR and atherosclerosis
23. Evidence for a monoclonal origin of human atherosclerotic plaques
24. Implications of the monoclonal character of human atherosclerotic plaques
25. Cytoplasmic sequestration of p53 in cytomegalovirus-infected human endothelial cells
26. Lymphocyte responses to chlamydia antigens in patients with coronary artery disease
27. Chlamydia pneumoniae and atherosclerosis-an update
28. Roles of infectious agents in atherosclerosis and restenosis
29. Cytomegalovirus and atherosclerosis
30. Induction of endothelial cell procoagulant activity by cytomegalovirus infection
31. Divergent patterns of ELAM-1, ICAM-1 and VCAM-1 expression on cytomegalovirus-infected endothelial cells
32. Advancing the battle against acute ischemic syndromes: A focus on the GP IIb-IIIa inhibitors
33. Role of platelet-inhibitor agents in coronary artery disease
34. Thrombosis and the pharmacology of antithrombotic agents
35. The pathogenesis of coronary artery disease and the acute coronary syndrome
36. Molecular and cellular biology of blood coagulation
37. Direct thrombin inhibitors for treatment of arterial thrombosis: Potential differences between bivalirudin and hurudin
38. Diagnosing and managing unstable angina
39. Cardiac troponin-T immunoassay for diagnosis of acute myocardial infarction
40. Emergency room triage of patients with acute chest pain by means of rapid testing for cardiac troponin T or troponin I
41. Applicability of cardiac troponin T and I for early risk stratification in unstable coronary artery disease
42. Unstable angina: A classification
43. Effectiveness of intravenous thrombolytic treatment in acute myocardial infarction
44. Randomized trial of intravenous streptokinase, oral aspirin, or neither among 17187 cases of suspected myocardial infarction
45. An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction
46. Late assessment of thrombolytic efficacy (LATE) study with alteplase 6 to 24 hours after onset of acute myocardial infarction
47. A randomized comparison of streptokinase versus tissue plasminogen activator versus anistreplase and of aspirin plus heparin versus aspirin alone among 41,299 cases of suspected acute myocardial infarction
48. A comparison of reteplase with alteplase for acute myocardial infarction
49. A factorial randomized trial of alteplase versus streptokinase and heparin versus no heparin among 12490 patients with acute myocardial infarction
50. In-hospital mortality and clinical course of 20891 patients with suspected acute myocardial infarction randomized between alteplase and streptokinase with or without heparin
51. Single-bolus tenecteplase compared with front-loaded alteplase in acute myocardial infarction: The ASSENT-2 double-blind randomized trial
52. Anti-platelet treatment with ticlopidine in unstable angina. A controlled multicenter clinical trial
53. A randomized, blinded, trial of clopidogrel versus aspirin in patients at risk of ischemic events (CAPRIE)
54. Clopidogrel loading dose regimens: Kinetic profile and pharmacodynamic response in healthy subjects
55. Single dose pharmacodynamics of clopidogrel
56. Randomized placebo-controlled trial of abciximab before and during coronary intervention in refractory unstable angina: The CAPTURE study
57. A comparison of aspirin plus tirofiban with aspirin plus heparin for unstable angina
58. Inhibition of the platelet glycoprotein IIb/IIIa receptor with tirofiban in unstable angina and non-Q-wave myocardial infarction
59. Inhibition of platelet glycoprotein IIb/IIIa with eptifibatide in patients with acute coronary syndrome
60. Randomized placebo-controlled trial of effect of eptifibatide on complications of percutaneous coronary intervention IMPACT II Integrilin to minimise platelet aggregation and coronary thrombosis-II
61. Effects of platelet glycoprotein IIb/IIIa blockade with tirofiban on adverse cardiac events in patients with unstable angina and acute myocardial infarction undergoing coronary angioplasty. Randomized efficacy study of tirofiban for outcomes and restenosis
62. Use of monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high risk coronary angioplasty
63. Platelet glycoprotein IIb/IIIa receptor blockade and low-dose heparin during percutaneous coronary revascularization
64. Streptokinase-induced platelet aggregation: Prevalence and mechanism
65. Profound inhibition of platelet aggregation with monoclonal antibody 7E3 Fab after thrombolytic therapy: Results of the thrombolysis and angioplasty in myocardial infarction (TAMI) 8 pilot study
66. Combined accelerated tissue-plasminogen activator and platelet glycoprotein IIb/IIIa integrin receptor blockade with Integrilin in acute myocardial infarction
67. Combined therapy with streptokinase and integrilin
68. Combining thrombolysis with the platelet glycoprotein IIb/IIIa inhibitor lamifiban: Results of the platelet aggregation receptor antagonist dose investigation and reperfusion gain in myocardial infarction (PARADIGM) trial
69. Abciximab facilitates the rate and extent of thrombolysis: Results of the thrombolysis in myocardial infarction (TIMI) 14 trial
70. Trial of abciximab with and without low-dose reteplase for acute myocardial infarction
71. ACC/AHA guidelines for the management of patients with acute myocardial infarction. A report of the American College of Cardiology/American Heart Association Task Force on Practice guidelines (Committee on Management of Acute Myocardial Infarction)
72. Low-molecular-weight heparin during instability in coronary artery disease
73. Comparison of low-molecular-weight heparin with unfractionated heparin acutely and with placebo for 6 weeks in the management of unstable coronary artery disease
74. Long-term low-molecular-mass heparin in unstable coronary-artery disease FRISC II prospective randomised multicentre study
75. A comparison of low-molecular-weight heparin with unfractionated heparin for unstable coronary artery disease
76. Enoxaparin prevents death and cardiac ischemic events in unstable angina/non-Q-wave myocardial infarction: Results of the thrombolysis in myocardial infarction (TIMI) 11B trial
77. Invasive compared with non-invasive treatment in unstable coronary-artery disease FRISC II prospective randomised multicentre study
78. One year follow-up of the ESSENCE trial (enoxaparin versus heparin in unstable angina and non-Q-wave myocardial infarction
79. Timolol-induced reduction in mortality and reinfarction in patients surviving acute myocardial infarction
80. A randomized trial of propranolol in patients with acute myocardial infarction. I. Mortality results
81. Immediate versus deferred beta-blockade following thrombolytic therapy in patients surviving acute myocardial infarction: Results of the thrombolysis in myocardial infarction (TIMI) II-B study
82. Metoprolol in acute myocardial infarction (MIAMI): A randomized placebo-controlled international trial
83. Randomized trial of intravenous atenolol among 16027 cases of suspected acute myocardial infarction: ISIS-1
84. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction
85. Effect of ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure
86. Effects of lisinopril and transdermal glyceryl trinitrate singly and together on 6-week mortality and ventricular function after acute myocardial infarction
87. The effect of the angiotensin-converting-enzyme inhibitor zofenopril on mortality and morbidity after anterior myocardial infarction
88. ISIS-4: A randomized factorial trial assessing early oral captopril, oral mononitrate, and intravenous magnesium sulphate in 58050 patients with suspected acute myocardial infarction
89. A clinical trial of the angiotensin-converting-enzyme inhibitor trandolapril in patients with left ventricular dysfunction after myocardial infarction
90. Effects of the early administration of enalapril on mortality in patients with acute myocardial infarction: Results of the cooperative new Scandinavian enalapril survival study II (CONSENSUS II)
91. Intravenous nitroglycerin therapy to limit myocardial infarct size, expansion, and complications: Effect of timing, dosage, and infarction location
92. Effect of intravenous nitrates on mortality following acute myocardial infarction: A multicenter study
93. Mortality and morbidity in patients receiving encainide, flecainide, or placebo: The cardiac arrhythmia suppression trial
94. Effect of the antiarrhythmic agent moricizine on survival after myocardial infarction
95. Effect of d-sotalol on mortality in patients with left ventricular dysfunction after recent and remote myocardial infarction
96. Randomized trial of outcome after myocardial infarction in patients with frequent or repetitive ventricular premature depolarisations: CAMIAT
97. Randomized trial of effect of amiodarone on mortality in patients with left ventricular dysfunction after recent myocardial infarction: EMIAT
98. Cholesterol management in theory and practice
99. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels
100. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia
101. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol events
102. Randomized trial of cholesterol lowering in 4444 patients with coronary artery disease: The Scandinavian simvastatin survival study (4S)
103. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels
104. Regression of coronary artery disease as a result of intensive lipid-lowering therapy in men with high levels of apolipoprotein B
105. Coronary angiographic changes with lovastatin therapy: The monitored atherosclerosis regression study (MARS)
106. Effects of monotherapy with HMG-CoA reductase inhibitor on the progression of coronary atherosclerosis as assessed by serial quantitative arteriography. The Canadian coronary atherosclerosis intervention trial
107. Effect of simvastatin on coronary atheroma: The multicenter anti-atheroma study (MAAS)
108. Effects of lipid lowering by pravastatin on progression and regression of coronary artery disease in symptomatic men with normal to moderately elevated serum cholesterol levels: The regression growth evaluation statin study (REGRESS)
109. Pravastatin limitation of atherosclerosis in the coronary arteries (PLAC I)
110. Relation between coronary artery stenosis assessed by visual, caliper, and computer methods and exercise capacity in patients with single vessel coronary artery disease
111. Angiographic progression of coronary artery disease and the development of myocardial infarction
112. Beneficial effects of cholesterol-lowering therapy on the coronary endothelium in patients with coronary artery disease
113. Simvastatin, an HMG-CoA reductase inhibitor, improves endothelial function within 1 month
114. Increased bioavailability of nitric oxide after lipid-lowering therapy in hypercholesterolemic patients: A randomized, placebo-controlled, double-blind study
115. Cholesterol reduction rapidly improves endothelial function after acute coronary syndromes
116. The mechanism of improvement in endothelial function by pravastatin: Direct effect or through cholesterol lowering
117. Coronary plaque disruption
118. Statins do more than just lower cholesterol
119. Pravastatin inhibits cellular cholesterol synthesis and increases low density lipoprotein receptor activity in macrophages: In vitro and in vivo studies
120. Lipid lowering and plaque regression: New insights into prevention of plaque disruption and clinical events in coronary disease
121. Fifteen year mortality in coronary drug project patients: Long-term benefit with niacin
122. Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol
123. Efficacy of gemfibrozil in dyslipidemic subjects with suspected heart disease. An ancillary study in the Helsinki heart study frame population
124. Secondary prevention by raising HDL cholesterol and reducing triglycerides in patients with coronary artery disease. The bezafibrate infarction prevention (BIP) study
125. Triglyceride as a risk factor for coronary artery disease